RESISTANCE TO AMPHOTERICIN-B - EMERGING CLINICAL AND MICROBIOLOGICAL PATTERNS

There has been an increasing number of reports of clinically significa nt amphotericin B (AmB) resistance in fungal pathogens, including Cand ida albicans. Concommitantly, advances in antifungal susceptibility te sting have led to an improved correlation between microbiologic and cl inical failure. Reports of AmB resistance, correlation of results and in vitro/in vivo correlations, mechanisms of resistance, and the trans mission Of resistant isolates within confined environments are reviewe d. Recommendations are given regarding the clinical settings in which AmB susceptibility testing should be considered.